PMID- 31932945
OWN - NLM
STAT- MEDLINE
DCOM- 20200325
LR  - 20200325
IS  - 1432-1963 (Electronic)
IS  - 0172-8113 (Linking)
VI  - 41
IP  - 1
DP  - 2020 Feb
TI  - [Molecular diagnostics of cytological specimens].
PG  - 39-45
LID - 10.1007/s00292-019-00733-3 [doi]
AB  - For lung carcinomas with certain molecular genetic alterations of the ALK, BRAF 
      or EGFR gene, there are targeted therapies that are also approved as first-line 
      therapy. Often, only limited sample material from biopsies is available for 
      molecular pathological testing. In some cases, biopsies with standard and 
      immunohistochemical staining have no or too low tumor content to be used for 
      PCR-based examinations or fluorescence in situ hybridization (FISH) analyses. In 
      such cases, cytological preparations such as bronchus brush smears, 
      transbronchial needle aspiration (TBNA), bronchial lavage, puncture smears from 
      lymph node or peripheral metastases, pleural effusion, ascites, and pericardial 
      effusion can be used. Standard stainings such as HE, Pappenheim, and Papanicolaou 
      as well as immunohistological preparations can be used after morphological 
      analysis and confirmatory diagnosis in order to extract DNA from them or to use 
      them for FISH analysis. A cytopathologist marks the tumor cell areas on the slide 
      beforehand. It is only possible to dissect these areas and extract DNA if the 
      proportion of tumor cells is sufficiently high. In order to carry out a FISH 
      analysis with the cytological preparations, the cytopathologist must draw in 
      areas as small as possible with more than 100 tumor cells. Already stained 
      sections are destained before the hybridization reaction. The aim is to achieve 
      comprehensive diagnostics even with limited starting material and to avoid 
      re-biopsies. Between 2016 and July 2019, 1711 next generation sequencing (NGS) 
      and FISH analyses were performed on cytological preparations at the Department of 
      Pathology of the University Hospital of Cologne. The success rate of 85.9% for 
      NGS examinations was slightly higher than the success rate of 82.8% for FISH 
      analyses.
FAU - Fassunke, Jana
AU  - Fassunke J
AD  - Institut fur Pathologie, Universitatsklinikum Koln, Kerpener Str. 62, 50924, 
      Koln, Deutschland. Jana.fassunke@uk-koeln.de.
FAU - Ball, Markus
AU  - Ball M
AD  - Institut fur Pathologie, Universitatsklinikum Koln, Kerpener Str. 62, 50924, 
      Koln, Deutschland.
FAU - Engels, Marianne
AU  - Engels M
AD  - Institut fur Pathologie, Universitatsklinikum Koln, Kerpener Str. 62, 50924, 
      Koln, Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Molekularpathologische Diagnostik an zytologischen Praparaten.
PL  - Germany
TA  - Pathologe
JT  - Der Pathologe
JID - 8006541
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/analysis
MH  - Biopsy, Fine-Needle
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*diagnosis/*metabolism/pathology
MH  - *Pathology, Molecular
OTO - NOTNLM
OT  - Cytodiagnosis
OT  - EGFR gene
OT  - Fluorescence in situ hybridization
OT  - Lung cancer
OT  - Next generation sequencing
EDAT- 2020/01/15 06:00
MHDA- 2020/03/26 06:00
CRDT- 2020/01/15 06:00
PHST- 2020/01/15 06:00 [pubmed]
PHST- 2020/03/26 06:00 [medline]
PHST- 2020/01/15 06:00 [entrez]
AID - 10.1007/s00292-019-00733-3 [pii]
AID - 10.1007/s00292-019-00733-3 [doi]
PST - ppublish
SO  - Pathologe. 2020 Feb;41(1):39-45. doi: 10.1007/s00292-019-00733-3.